What Is The Predicted Revenue Outlook For The Global Chronic Pruritus Therapeutics Market To Surpass $14.36 Billion?
Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Projected Valuation Of The Chronic Pruritus Therapeutics Market In The Coming Years?
In recent times, the market size of chronic pruritus therapeutics has seen robust growth. It is projected to expand from $10.17 billion in 2024 to $10.91 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.3%. The historical growth trend can be ascribed to factors such as a surge in chronic pruritus incidence, escalating demand for efficient therapies, an uptick in regulatory consents, augmented product clearances, and a rise in mergers, collaborations, and acquisitions among industry players.
The market size for chronic pruritus therapeutics is predicted to experience substantial growth in the coming years, reaching $14.36 billion by 2029 with a compound annual growth rate (CAGR) of 7.1%. The expected growth during this forecast period can be credited to factors such as increasing awareness, a rise in atopic dermatitis cases, heightened emphasis on personalized medicine, a surge in dermatological condition prevalence, and an expanding patient population. Key trends anticipated for this period encompass the launch of ground-breaking medicines, the manufacturing of unique biologics and targeted treatments, progression in technology, the introduction of state-of-the-art drug delivery systems, partnerships between pharmaceutical corporations and research organizations, and the advent of digital health technologies such as telemedicine.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21147&type=smp
Which Market Dynamics Are Playing A Critical Role In The Growth Of The Chronic Pruritus Therapeutics Market?
The increase in cases of atopic dermatitis is believed to drive the expansion of the chronic pruritus therapeutics market. Characterized by dryness, redness, irritation, and itching, atopic dermatitis (AD) is a persistent skin inflammation often seen in individuals with a familial history of allergies, asthma, or hay fever. This increase is linked to several factors such as inherited susceptibility, changes in the environment, lifestyle habits, the hygiene hypothesis, higher exposure to allergens, and imbalances in skin microbiome. Chronic pruritus therapeutics help to alleviate the continuous itching related to atopic dermatitis by focusing on the root inflammatory pathways, decreasing skin irritation, and enhancing patient comfort. For instance, as stated by the International Eczema Council, a nonprofit organization based in the U.S. in 2022, roughly 223 million people around the world had atopic dermatitis (GBD 2022). This included about 43 million children between the ages 1-4, underlining the disease’s high occurrence in early years of life. Hence, the growing cases of atopic dermatitis are fueling the expansion of the chronic pruritus therapeutics market.
Which Sub-Segments Are Driving Growth Within The Chronic Pruritus Therapeutics Market?
The chronic pruritus therapeuticsmarket covered in this report is segmented –
1) By Product Type: Corticosteroid; Antihistamine; Local Anesthetic; Counterirritant; Immunosuppressant; Calcineurin Inhibitors; Other Product Types
2) By Disease Type: Atopic Dermatitis; Allergic Contact Dermatitis; Urticaria; Other Disease Types
3) By Distribution Channel: Hospital Pharmacies; Drug stores And Retail Pharmacies; Online Providers
Subsegments:
1) By Corticosteroid: Topical Corticosteroids; Oral Corticosteroids; Injectable Corticosteroids
2) By Antihistamine: First-Generation Antihistamines; Second-Generation Antihistamines
3) By Local Anesthetic: Topical Local Anesthetics; Injectable Local Anesthetics
4) By Counterirritant: Menthol-Based Counterirritants; Camphor-Based Counterirritants
5) By Immunosuppressant: Systemic Immunosuppressants; Topical Immunosuppressants
6) By Calcineurin Inhibitors: Tacrolimus-Based Therapy; Pimecrolimus-Based Therapy
7) By Other Product Types: Biologic Therapies; Emerging Novel Therapies
What Future-Focused Trends Are Anticipated In The Chronic Pruritus Therapeutics Market?
Prominent firms engaged in the chronic pruritus therapeutics sector are directing their efforts towards the creation of novel formulations, such as intravenous (IV) injections, to improve treatment’s effectiveness and provide rapid relief to patients. Antihistamines or corticosteroids can be directly administered into the bloodstream using IV injections, providing immediate relief from itching and reducing inflammation. For instance, in September 2023, Cara Therapeutics Inc., an American therapeutics manufacturer, announced that its partner firm, Maruishi Pharmaceutical Co. Ltd., a Japanese pharmaceutical company, obtained approval from Japan’s Ministry of Health, Labour and Welfare for the Korsuva IV injection syringe. This formulation, intended to treat pruritus in hemodialysis patients, received approval based on the positive results from a Phase 3 clinical trial conducted in collaboration with Kissei Pharmaceutical Co., Ltd. The trial results highlighted significant reductions in itchiness when compared to a placebo and showed good patient tolerance. Furthermore, the approval activates a milestone payment of $1.5 million to Cara Therapeutics, the original developer of Korsuva, per their licensing terms with Maruishi.
Which Players Are Shaping The Competitive Landscape Of The Chronic Pruritus Therapeutics Market?
Major companies operating in the chronic pruritus therapeutics market are Pfizer Incorporated, AbbVie Inc., Sanofi S.A., Novartis Aktiengesellschaft, GlaxoSmithKline plc, Toray Industries Inc., CSL Behring LLC, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Ipsen S.A., Incyte Corporation, Cipla Limited, H. Lundbeck A/S, Sumitomo Pharma Co. Ltd., Mallinckrodt Pharmaceuticals plc, Kissei Pharmaceutical Co. Ltd., Asana BioSciences LLC, Vanda Pharmaceuticals Inc., Dermavant Sciences Inc., Galderma Laboratories L.P., Cara Therapeutics Inc., Avior Bio Inc., Trevi Therapeutics Inc.
Access The Complete Report Here:
https://www.thebusinessresearchcompany.com/report/chronic-pruritus-therapeutics-global-market-report
How Do Regional Dynamics Influence The Chronic Pruritus Therapeutics Market Performance?
North America was the largest region in the chronic pruritus therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the chronic pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=21147&type=smp
Browse Through More Reports Similar to the Global Chronic Pruritus Therapeutics Market 2025, By The Business Research Company
Chronic Myeloid Leukemia Cml Treatment Global Market Report 2025
Chronic Cough Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/chronic-cough-global-market-report
Late Stage Chronic Kidney Disease Drugs Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
